Suppressive roles of A3AR and TMIGD3 i1 in osteosarcoma malignancy.
作者信息
Ranjan Atul, Iyer Swathi V, Iwakuma Tomoo
机构信息
a Department of Cancer Biology , University of Kansas Medical Center , Kansas City , KS , USA.
出版信息
Cell Cycle. 2017 May 19;16(10):903-904. doi: 10.1080/15384101.2017.1308153. Epub 2017 Mar 29.
Abstract
摘要
相似文献
1
Suppressive roles of A3AR and TMIGD3 i1 in osteosarcoma malignancy.
Cell Cycle. 2017 May 19;16(10):903-904. doi: 10.1080/15384101.2017.1308153. Epub 2017 Mar 29.
2
Genome-wide RNAi screening identifies TMIGD3 isoform1 as a suppressor of NF-κB and osteosarcoma progression.
Nat Commun. 2016 Nov 25;7:13561. doi: 10.1038/ncomms13561.
3
Molecular Mechanisms and microRNAs in Osteosarcoma Pathogenesis.
Biochemistry (Mosc). 2016 Apr;81(4):315-28. doi: 10.1134/S0006297916040027.
4
Ezrin/NF-κB Pathway Regulates EGF-induced Epithelial-Mesenchymal Transition (EMT), Metastasis, and Progression of Osteosarcoma.
Med Sci Monit. 2018 Apr 9;24:2098-2108. doi: 10.12659/msm.906945.
5
6
EFEMP1 promotes the migration and invasion of osteosarcoma via MMP-2 with induction by AEG-1 via NF-κB signaling pathway.
Oncotarget. 2015 Jun 10;6(16):14191-208. doi: 10.18632/oncotarget.3691.
7
Secreted Frizzled-Related Protein 2 (sFRP2) promotes osteosarcoma invasion and metastatic potential.
BMC Cancer. 2016 Nov 8;16(1):869. doi: 10.1186/s12885-016-2909-6.
8
Activation of TNF-α/NF-κB axis enhances CRL4B E3 ligase activity and regulates cell cycle progression in human osteosarcoma cells.
Mol Oncol. 2018 Apr;12(4):476-494. doi: 10.1002/1878-0261.12176. Epub 2018 Feb 20.
9
Wnt, osteosarcoma, and future therapy.
J Am Acad Orthop Surg. 2012 Jan;20(1):58-9. doi: 10.5435/JAAOS-20-01-058.
10
Correlation of c-fos, p53, and PCNA expression with treatment outcome in osteosarcoma.
J Surg Oncol. 2000 Feb;73(2):125-6. doi: 10.1002/(sici)1096-9098(200002)73:2<125::aid-jso14>3.0.co;2-5.
引用本文的文献
1
A Comprehensive Analysis Exploring the Impact of an Immunogenic Cell Death-Related Panel for Ovarian Cancer.
Mol Biotechnol. 2025 Jun;67(6):2520-2535. doi: 10.1007/s12033-024-01215-5. Epub 2024 Aug 7.
2
Species dependence of A adenosine receptor pharmacology and function.
Purinergic Signal. 2023 Sep;19(3):523-550. doi: 10.1007/s11302-022-09910-1. Epub 2022 Dec 20.
3
Selective A Adenosine Receptor Antagonist Radioligand for Human and Rodent Species.
ACS Med Chem Lett. 2022 Mar 2;13(4):623-631. doi: 10.1021/acsmedchemlett.1c00685. eCollection 2022 Apr 14.
4
Direct Comparison of (N)-Methanocarba and Ribose-Containing 2-Arylalkynyladenosine Derivatives as A Receptor Agonists.
ACS Med Chem Lett. 2020 Feb 14;11(10):1935-1941. doi: 10.1021/acsmedchemlett.9b00637. eCollection 2020 Oct 8.
本文引用的文献
1
Genome-wide RNAi screening identifies TMIGD3 isoform1 as a suppressor of NF-κB and osteosarcoma progression.
Nat Commun. 2016 Nov 25;7:13561. doi: 10.1038/ncomms13561.
2
Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies.
Crit Rev Oncog. 2015;20(3-4):173-97. doi: 10.1615/critrevoncog.2015013713.
3
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success.
J Clin Oncol. 2015 Sep 20;33(27):3029-35. doi: 10.1200/JCO.2014.59.4895. Epub 2015 Aug 24.
4
The A3 adenosine receptor: history and perspectives.
Pharmacol Rev. 2015;67(1):74-102. doi: 10.1124/pr.113.008540.
5
Metastatic potential of tumor-initiating cells in solid tumors.
Front Biosci (Landmark Ed). 2011 Jan 1;16(5):1927-38. doi: 10.2741/3831.
6
An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B.
Oncogene. 2004 Apr 1;23(14):2465-71. doi: 10.1038/sj.onc.1207355.
7
Signaling pathway from the human adenosine A(3) receptor expressed in Chinese hamster ovary cells to the extracellular signal-regulated kinase 1/2.
Mol Pharmacol. 2002 Nov;62(5):1137-46. doi: 10.1124/mol.62.5.1137.
Zotero 插件